Business Wire

EGYPTIAN-TOURISM

16.3.2023 14:11:45 CET | Business Wire | Press release

Share
Egypt Beats Classic UK Holiday Destinations in Both Attractiveness and Price

The most popular foreign destinations for British holidaymakers are Italy and Spain. However, what many travellers do not know: For the price they spend on a holiday in these countries, they could experience more luxury and adventure in Egypt.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230216005515/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Winter in Egypt (Photo: Business Wire)

What Brits pay for their holidays abroad

Brits love to travel, but how much do they actually spend on their holidays? According to National Institute of statistics (Ine), the British invested an average of £1,0001 per person on a trip in 2021. However, a one-week stay including meals in a three-star hotel in Italy, for example, can cost up to £1,300 even in the low season. And that doesn't even include sightseeing, theatre tickets or museum visits.

In Egypt, two people can spend seven nights in a five-star hotel for less than the average price of a holiday in an Italian coastal region - all-inclusive, of course. The return flight from a major UK city is also included here. This leaves a lot of the budget for excursions and activities.

From paradisiacal beaches to the impressive expanse of the desert

Egypt has a lot to offer for all travelers - whether they are sun worshippers looking to relax on the beautiful coasts or culture vultures in search of ancient sites steeped in history. "Over the past two years, when we had restrictions on travel due to the pandemic, Egypt has been improving its travel infrastructure and working to expand what it has to offer visitors," says Amr El-Kady, managing director of the Egyptian Tourism Authority. "Even tourists who have visited Egypt before will now be able to discover many new options for things to do and interesting things to see. There are numerous, fantastic new accommodations available as domiciles."

For beach and sea lovers, the entire Egyptian coast is an ideal destination. You'll find plenty of white sandy beaches and warm, crystal-clear waters on both the Mediterranean and the Red Sea. From the beach resorts in Sharm El Sheikh on the Sinai Peninsula and Hurghada on Egypt's east coast, you can enjoy breathtaking views over the Red Sea. From here, you can also explore the mystical mountain regions inland. The Red Sea is also home to some of the most beautiful coral reefs in the world and can be explored by both amateur and professional divers. The Mediterranean coast from Alexandria to Marsa Matruh also beckons with turquoise waters and seemingly endless sandy beaches that invite you to swim, dive and sunbathe.

Those who prefer to discover and enjoy the incomparable beauty of the desert will not be disappointed either and can expect an experience like from 1001 Nights. In the Sinai desert, hiking and camel safaris offer an unforgettable experience for outdoor enthusiasts.

Tradition and history in the cities of the pharaohs

Among the most impressive historical sites is the magnificent city of Luxor with its spectacular sights such as the Valley of the Kings, the Temple of Karnak, and the legendary Luxor Temple. For a special experience, take a hot air balloon ride for a majestic view of the city on the Nile from above.

Fans of city trips should have Cairo on their agenda: In the Egyptian capital, millennia-old relics of antiquity meet the modern culture of the Middle East. The Great Sphinx and the Pyramids of Giza - the only remaining wonder of the ancient world - are unique buildings and an impressive testimony to ancient architecture. The history of the country is also presented in detail in the Egyptian Museum: It houses over 120,000 artefacts, including the treasures from Tutankhamun's tomb.

The Khan El Khalili bazaar is one of the oldest and most famous markets in the Middle East: here, holidaymakers can not only find authentic souvenirs but also enjoy the specialties of the local cuisine and get to know contemporary Egyptian culture.

Anyone looking for a multifaceted, historical and affordable travel destination should try Egypt to see for themselves the rich variety of this country with their own eyes and senses.

1 Ine (2022) Gasto de los turistas internacionales segun pais de residencia. Taken from: https://www.ine.es/jaxiT3/Datos.htm?t=10838#!tabs-tabla

– ENDE –

For further information:
https://www.experienceegypt.eg/

About the Egyptian Tourism Board

The Egyptian Tourism Board, established in 1981, is a regulatory body affiliated with the Ministry of Tourism. Its mission is to stimulate international tourism by promoting Egypt's rich history and civilization and highlighting the country's many tourist attractions. It also aims to promote domestic tourism, raise awareness of tourism throughout the country and strengthen the link between Egyptians and their heritage.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230216005515/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye